U.S. Lab Availability Declines for First Time in Years

Why It Matters

The shift signals the first real recovery in life‑sciences real estate, unlocking value for owners and guiding capital toward higher‑quality, tech‑enabled lab spaces.

Key Takeaways

• Lab availability down 2 M sq ft since mid‑2025, ending oversupply
• Newer labs (post‑2020) shed 2.6 M sq ft; older stock added 0.7 M
• AI and robotics firms now major lab tenants
• Equity markets warming to biotech fuels capital inflow
• Supply, not demand, is now the sector's primary challenge

Pulse Analysis

The U.S. life‑sciences real estate market has long been haunted by excess lab space, a legacy of aggressive development during the pandemic boom. JLL’s latest data shows a decisive reversal, with total availability dropping by about two million square feet since mid‑2025. This contraction reflects a broader correction as investors reassess risk and as biotech firms, buoyed by stronger equity markets, resume leasing activity. The trend marks a pivotal moment for a sector that has struggled with vacancy rates above 10 percent for several years.

A deeper dive reveals a pronounced "flight to quality" that is reshaping the inventory landscape. Buildings completed after 2020 have collectively shed 2.6 million sq ft of space, indicating that newer, purpose‑built labs are attracting the most active tenants. In contrast, pre‑2000 properties have added roughly 700,000 sq ft back to the market, suggesting that older, less adaptable facilities are being repurposed or left idle. Simultaneously, the tenant mix is evolving: AI, robotics and other high‑tech firms are increasingly occupying lab spaces, blurring the line between traditional biotech and emerging "tough tech" sectors.

For developers and investors, the implications are clear. Capital is flowing back into high‑grade, flexible lab environments, while older assets may require significant upgrades or repositioning to stay competitive. Lease rates are expected to stabilize, and the focus will shift from attracting any tenant to securing those with long‑term, technology‑driven growth prospects. Stakeholders who align their portfolios with this supply‑driven reality stand to benefit from higher occupancy, stronger rents, and a more resilient life‑sciences real estate market.